Not All Breast Cancers Are the Same: What Your Diagnosis Really Means
reprint from an article posted online by Katie Couric Media
I do not often copy other people’s posts, but when I do, I do it because I think it’s important information. This very long article was posted online by Katie Couric Media. The online article can be found at: Understanding Breast Cancer Terminology
Not All Breast Cancers Are the Same: What Your Diagnosis Really Means
Location, biology, and subtype aren’t just medical jargon — they’re the keys to more-personalized treatment and better-informed decisions.
By Katie Couric Media June 14, 2026
When you hear the words “breast cancer,” most people picture a single disease: One diagnosis, one treatment path, one experience. But there are several types of breast cancer — and the variations among them have a huge impact on how they’re treated.
The truth is, “breast cancer” is an umbrella term for a number of distinct diseases that originate in breast tissue. Two people sitting in the same oncologist’s waiting room, both told they have breast cancer, may have tumors with almost nothing in common: different biology, different treatment plans, and different long-term outlooks. While that might sound frightening, it’s actually the foundation of something hopeful — the more precisely doctors can characterize a patient’s breast cancer, the more precisely they can treat it.
So, what are the features of breast cancer that matter most? Ultimately it comes down to where the cancer is, and how it grows. LIFE, INTERRUPTED
Understanding early vs. metastatic breast cancer
The first question doctors need to determine is location — not just where the tumor is, but whether the cancer has traveled beyond the breast.
Early breast cancer (EBC) is found in the breast and sometimes in nearby lymph nodes, but has not spread to other parts of the body. It accounts for the vast majority of breast cancer diagnoses, and — importantly — many people with early breast cancer can be treated with curative intent. For many people diagnosed with early breast cancer, the goal of treatment is to eliminate the cancer and prevent it from recurring.
Metastatic breast cancer (MBC) has spread beyond the breast and nearby lymph nodes to other parts of the body — most commonly the bones, lungs, or liver. There are two pathways to an MBC diagnosis. Some people are diagnosed with metastatic disease from the start — called de novo MBC. Others develop MBC after being treated for early breast cancer, when cancer cells that weren’t eliminated by initial treatment eventually spread. This is called a distant recurrence. Both pathways lead to the same treatment goals, though the individual journey may look different. MBC is not curable, but it is treatable. Treatment goals shift accordingly and the focus moves to controlling it, managing symptoms, and preserving quality of life for as long as possible. For many people, it can become a long-term, manageable condition.
The biology behind a cancer diagnosis
The second important consideration is tumor biology — specifically, what’s fueling the cancer’s growth at a molecular level. This is where something known as receptor status comes in.
Receptors are proteins on or inside our cells that receive signals. In breast cancer, two types of receptors are particularly important:
Hormone receptors (HR): Some breast cancer cells have receptors that bind to the hormones estrogen or progesterone, using them as fuel to grow. Think of hormone receptors like a socket: estrogen acts as a plug, and when the two connect, the cell gets a signal to grow. Tumors that have these receptors are called hormone receptor-positive (HR+); those that don’t are HR-negative (HR-). Nearly 80% of all breast cancer diagnoses are HR+.
HER2: Human epidermal growth factor receptor 2, or HER2, is a protein that, when overexpressed, can accelerate cancer cell growth. HER2 works differently than the hormone receptor. Rather than waiting for a signal, cells that produce too much HER2 have a growth switch that’s effectively stuck in the on position. Tumors with high levels of HER2 are HER2- positive (HER2+); those without it are HER2-negative (HER2-).
Together, these markers define a tumor’s receptor status — a kind of biological fingerprint that tells doctors how the cancer is likely to behave and which treatments are most likely to work.
The most common subtype is HR-positive, HER2-negative (HR+/HER2-), accounting for roughly 70 percent of all cases. Less common subtypes include HER2-positive breast cancer and triple-negative breast cancer (TNBC) — a subtype that’s doesn’t have estrogen, progesterone, or HER2 receptors; these require a different treatment approach entirely.
But it doesn’t end there: Two people with HR+/HER2- breast cancer can still have very different treatment journeys, shaped by other features of their individual tumor — its size, its grade, and activity of other specific genes. As the field learns more about these nuanced differences, treatment is becoming increasingly personalized.
What breast cancer treatment actually looks like
For people with early breast cancer, treatment typically begins with surgery. Whether a surgeon recommends a lumpectomy (removing the tumor and a small margin of surrounding tissue) or a mastectomy (removing all or part of one or both breasts) depends on many factors. Choosing one over the other does not mean the disease is more or less serious.
Surgery is often followed by radiation, particularly after a lumpectomy. Because surgery alone cannot always eliminate every microscopic cancer cell, radiation may help reduce the risk of recurrence even after a tumor has been successfully removed.
Chemotherapy is part of some early breast cancer treatment plans, but not all. For HR+/HER2- breast cancer specifically, advances in genomic testing have helped doctors identify which patients are likely to benefit from chemotherapy and which are not — sparing many people from treatment they don’t need. It’s a concrete example of how knowing a tumor’s biology shapes the treatment plan.
After surgery, radiation, and chemotherapy, patients with EBC often take endocrine therapy (ET). While the other treatments are relatively short, ET typically lasts five to ten years, depending on a patient’s individual risk factors. That extended timeline matters: the therapy is intended to help reduce the risk of recurrence long after the cancer itself is no longer visible or detectable. The challenge is that staying on it requires discipline during a period when most people simply want to move on.
For some patients — particularly those whose cancer had spread to nearby lymph nodes or whose tumor has other features that indicate a higher risk of recurrence — endocrine therapy may be combined with a targeted medication that works alongside it and is intended to help reduce that risk.
Treatment for metastatic breast cancer differs from treatment for early breast cancer because the goal is long-term disease control rather than cure. Patients may have surgery and remain on ongoing systemic therapies — including endocrine therapy, targeted medicines, chemotherapy, immunotherapy, or combinations of these treatments. If a treatment stops working, patients are often switched to a different regimen.
What recurrence means — and what it doesn’t
Even when early breast cancer is treated successfully, there is always some risk of recurrence, which is when the cancer returns after treatment. Recurrence can be local, meaning it comes back in or near the breast, or distant, meaning it appears elsewhere in the body. Distant recurrence is considered metastatic breast cancer.
Several factors influence recurrence risk, including the size and grade of the original tumor, whether it had spread to nearby lymph nodes, and its receptor status. Understanding your personal recurrence risk is one of the most important conversations to have with your care team — not because it predicts the future, but because it shapes the treatment decisions designed to protect you in the longer-term.
If cancer does return, it’s not a reflection of anything the patient did or didn’t do. It reflects the nature of the disease itself. And today, for patients facing recurrence, the treatment options look meaningfully different than it did even just a decade ago, with a growing number of options that didn’t previously exist.
Questions you should bring to your doctor
If you or someone you love has been diagnosed with breast cancer, here are four questions that cut right to what matters most:
1. What is my breast cancer subtype? The answer shapes everything that follows.
2. What is my recurrence risk? And how does my treatment plan address it?
3. What does my treatment timeline look like? Including the longer-term therapies that extend beyond surgery.
4. Are there additional tests — genomic or otherwise — that could help personalize my treatment?
Breast cancer is complex. But complexity, when understood, enables more targeted treatment. The more you know about the biology of your breast cancer, the better equipped you are to ask the right questions, advocate for yourself, and engage as an informed partner in your own care.
This article is intended for informational purposes only and does not constitute medical advice. Please consult your healthcare provider for guidance specific to your situation.